December 16, 2022 02:59 PM EST
FDA+

FDA sched­ules Covid-19 vac­cine ad­comm to dis­cuss po­ten­tial mod­i­fi­ca­tions and boost­ers

Paul Schloesser

Associate Editor

Af­ter the two years of suc­cess­ful up­take of Covid-19 vac­cines, the FDA is now look­ing to stream­line the reg­i­men of pri­ma­ry se­ries, boost­ers and bi­va­lents …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times